Autoantibodies to the islet cell antigen SOX–13 are associated with duration but not type of diabetes


Diabetic Medicine
Volume 20 Issue 3 Page 198 – March 2003

Aims The autoantigen SOX–13 of the SRY–related high mobility group box is a low–frequency reactant in sera from patients with Type 1 diabetes. We further investigated the potential diagnostic role of anti–SOX–13, and in particular its ability to distinguish Type 1 from Type 2 diabetes, in two large, well–characterized cohorts.

Methods SOX–13 autoantibody status was ascertained using a radioimmunoprecipitation assay in (i) a random sample of 546 participants in an Australian community–based study (the Fremantle Diabetes Study; FDS) of whom 119 had Type 1 and 427 Type 2 diabetes, and (ii) a sample of 333 subjects with Type 2 diabetes from the United Kingdom Prospective Diabetes Study (UKPDS) stratified by age, anti–glutamic acid decarboxylase (GAD) and islet cell antibody (ICA) status, and requirement for insulin therapy within 6 years of diagnosis.

Results The frequencies of anti–SOX–13 in the FDS subjects were 16.0% and 14.8% for Type 1 and Type 2 patients, respectively, and levels were similar. In the UKPDS subjects, the frequency was 4.5%. In a logistic regression model involving demographic, anthropometric and metabolic variables, only diabetes duration was significantly associated with anti–SOX–13 positivity, especially for duration > 5 years (P < 0.002). When the coexistence of autoantibodies was assessed in the two study samples, there were no significant associations between anti–SOX–13 and ICA, anti–GAD or ICA512/IA–2.

Conclusions Whilst the frequency of anti–SOX–13 may be increased in some populations of diabetic patients, this reactivity does not usefully distinguish Type 1 from Type 2 diabetes. However, the association with diabetes duration suggests that anti–SOX–13 may be a non–specific marker of tissue damage associated with chronic hyperglycaemia.